Amgen awards Abelson-Taylor DTC for chemo drugs

Share this article:
Amgen has named Abelson-Taylor agency of record for DTC on two oncology brands.  The Chicago-based independent is working on TV and print advertising for Neulasta, previously handled by Euro RSCG Messner, and Aranesp, which has not previously run consumer advertising. Abelson-Taylor handles professional advertising for Neulasta and executed the U.S. and global launch of Aranesp in 1999. Better-known for its award-winning professional advertising, the firm launched its DTC capability last year, landing the DTC work for TPNA's Rozerem. Sales of Aranesp drove a 20% increase in Amgen’s profit for the fourth quarter, the company reported today. The anemia drug, which competes with Johnson & Johnson’s Procrit, pulled in $873 million worldwide. Amgen also cited increased demand for Neulasta, a white blood cell boosting anti-infective for chemo patients. Neulasta and Neupogen together took in $928 million as Neulasta sales benefited from a National Comprehensive Cancer Network advisory urging earlier use of the drug.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions